Biome Australia Posts $18.4M Sales and $215K Net Profit in FY25
Biome Australia Limited has reported its first net profit alongside a 41.6% jump in sales revenue, driven by strong domestic growth and expanding international partnerships.
- First net profit after tax of $214,656
- Sales revenue climbs 41.6% to $18.4 million
- International sales grow 69%, reaching $1.5 million
- Record quarterly sales exceeding $5 million in June quarter
- Launch of new practitioner-only product range and proprietary probiotic strain
A Milestone Year for Biome Australia
Biome Australia Limited (ASX, BIO), a specialist in microbiome health products, has announced a landmark financial year with its first-ever net profit after tax of $214,656 for FY25. This achievement caps a year of robust growth, with sales revenue soaring 41.6% to $18.4 million, underscoring the company’s accelerating momentum since its founding in 2018.
The company’s performance was punctuated by a record June quarter, where sales topped $5 million, including a standout $2.1 million month in June alone. This strong finish propelled Biome into FY26 with an annualised sales run rate exceeding $20 million, positioning it well on the path to meet its Vision 27 goal of $75 million cumulative sales over three years.
Domestic Leadership and Market Penetration
Biome’s flagship Activated Probiotics brand has cemented itself as the number two player in total probiotic revenue within Australian community pharmacies, with domestic sell-through increasing by over 50% in FY25. The company attributes this success to a combination of innovative, clinically backed products, exceptional customer service, and targeted health solutions that resonate with consumers and health professionals alike.
International Expansion Gains Traction
International sales surged by approximately 69% to $1.5 million, driven by strategic partnerships across Canada, Ireland, the United Kingdom, and New Zealand. These alliances open thousands of new pharmacy and health food outlets for Biome’s products, setting the stage for significant growth in FY26. Key partners include major Canadian health retailers such as Pure Pharmacy Group and Healthy Planet Group, Ireland’s Uniphar network, and New Zealand’s Propharma, the largest pharmacy wholesaler in the country.
Innovation and Product Development
FY25 also saw Biome launch Activated Therapeutics, a new practitioner-only range targeting specific health concerns like perimenopause and gastrointestinal reflux. The company successfully completed development of its proprietary probiotic strain, Lactobacillus plantarum BMB18, now registered with Germany’s DSMZ culture bank, which offers promising licensing opportunities and underscores Biome’s commitment to research-driven innovation.
Founder and Managing Director Blair Vega Norfolk expressed pride in the company’s achievements, highlighting the transition from a start-up to a sustainable, profitable growth company. He emphasized the importance of education, clinical backing, and international partnerships in driving Biome’s success and future potential.
Looking Ahead
With a solid financial foundation and expanding global footprint, Biome Australia is poised to accelerate its growth trajectory. The company’s focus on evidence-based products and strategic market expansion suggests it is well-positioned to become a leading global player in probiotics and targeted health solutions.
Bottom Line?
Biome’s first profit and international momentum signal a promising leap toward its Vision 27 ambitions.
Questions in the middle?
- How will Biome scale its international partnerships to sustain growth beyond FY26?
- What impact will the proprietary probiotic strain BMB18 have on future licensing revenue?
- Can Biome maintain its gross margin improvements amid expanding product lines and markets?
